Scott R. Solomon
About
Scott R. Solomon is a scholar working on Hematology, Oncology and Immunology.
According to data from OpenAlex, Scott R. Solomon has authored 197 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 141 papers in Hematology, 85 papers in Oncology and 49 papers in Immunology. Recurrent topics in Scott R. Solomon's work include Hematopoietic Stem Cell Transplantation (91 papers), Acute Myeloid Leukemia Research (61 papers) and CAR-T cell therapy research (42 papers). Scott R. Solomon is often cited by papers focused on Hematopoietic Stem Cell Transplantation (91 papers), Acute Myeloid Leukemia Research (61 papers) and CAR-T cell therapy research (42 papers). Scott R. Solomon collaborates with scholars based in United States, Switzerland and Germany. Scott R. Solomon's co-authors include Asad Bashey, Lawrence E. Morris, H. Kent Holland, Stacey Brown, Xu Zhang, Connie A. Sizemore, Melhem Solh, A. John Barrett, Melissa Sanacore and Karen Manion and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.
In The Last Decade
Scott R. Solomon
182 papers receiving 4.1k citations
Hit Papers
Peers
Scott R. Solomon
Sally Arai United States
Asad Bashey United States
Francesco Lanza Italy
Carol Ann Huff United States
A Schattenberg Netherlands
Francis Ayuk Germany
Joseph P. McGuirk United States
RE Champlin United States
Panagiotis Kottaridis United Kingdom
Harry Dolstra Netherlands
Citations per year, relative to Scott R. Solomon Scott R. Solomon (= 1×)
peers
Sally Arai
Countries citing papers authored by Scott R. Solomon
Since
Specialization
Citations
This map shows the geographic impact of Scott R. Solomon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott R. Solomon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott R. Solomon more than expected).
Fields of papers citing papers by Scott R. Solomon
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Scott R. Solomon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott R. Solomon. The network helps show where Scott R. Solomon may publish in the future.
Co-authorship network of co-authors of Scott R. Solomon
This figure shows the co-authorship network connecting the top 25 collaborators of Scott R. Solomon. A scholar is included among the top collaborators of Scott R. Solomon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott R. Solomon. Scott R. Solomon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Zhang, Mei‐Jie, Rizwan Romee, Navneet S. Majhail, et al.. (2025). Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. Transplantation and Cellular Therapy. 31(3). 174.e1–174.e12.
2.
McCurdy, Shannon R., Scott R. Solomon, Brian C. Shaffer, et al.. (2025). Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic Transplantation. Transplantation and Cellular Therapy. 32(1). 74.e1–74.e14.
3.
Solomon, Scott R., Bayard L. Powell, Catherine Lai, et al.. (2024). CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial. Cancers. 16(5). 915–915.
4.
Baker, Steven Andrew, Asad Bashey, Lizamarie Bachier‐Rodriguez, et al.. (2024). Prophylactic Corticosteroids Allow Safe Outpatient Administration of Axicabtagene Ciloleucel with Comparable Toxicities to Other CAR-T Therapies in Large Cell Lymphoma. Blood. 144(Supplement 1). 2363–2363.
5.
Landsburg, Daniel J., Richard T. Maziarz, Amy Moskop, et al.. (2024). Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry. Blood. 144(Supplement 1). 4398–4398.
6.
Solomon, Scott R., Lizamarie Bachier‐Rodriguez, Asad Bashey, et al.. (2024). Impact of Graft-Versus-Host Disease on Relapse and Nonrelapse Mortality Following Posttransplant Cyclophosphamide-Based Transplantation. Transplantation and Cellular Therapy. 30(9). 903.e1–903.e9.
7.
Solh, Melhem, Asad Bashey, H. Kent Holland, Lawrence E. Morris, & Scott R. Solomon. (2022). Allogeneic Hematopoietic Cell Transplantation (HCT) for Adult Patients with Acute Lymphoblastic Leukemia: Impact of Timely Transplantation on Survival Outcomes. Transplantation and Cellular Therapy. 28(3). S40–S40.
8.
Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2022). Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study. Transplantation and Cellular Therapy. 28(3). S188–S189.
9.
Solomon, Scott R., Michael T. Aubrey, Xu Zhang, et al.. (2022). Lineage-Specific Relapse Prediction After Haploidentical Transplantation With Post-Transplant Cyclophosphamide Based on Recipient HLA-B-Leader Genotype and HLA-C-Group KIR Ligand. Transplantation and Cellular Therapy. 28(9). 601.e1–601.e8.
10.
Solh, Melhem, Scott R. Solomon, Asad Bashey, et al.. (2022). Extracorporeal photopheresis (ECP) improves overall survival in the treatment of steroid refractory acute graft-versus-host disease (SR aGvHD). Bone Marrow Transplantation. 58(2). 168–174.
11.
Solomon, Scott R., Amitkumar Mehta, Jeremy S. Abramson, et al.. (2021). Experience of Prior Anti-CD19 Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Non-Hodgkin Lymphoma (B-NHL) Receiving Lisocabtagene Maraleucel (liso-cel), an Investigational Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Product. Transplantation and Cellular Therapy. 27(3). S207–S208.
12.
Cortes, Jörge E., Donna E. Hogge, Scott R. Solomon, et al.. (2021). Five-Year Final Results of a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML): Outcomes By Age Subgroup and Among Responders. Transplantation and Cellular Therapy. 27(3). S126–S127.
13.
Jain, Nitin, Hagop M. Kantarjian, Scott R. Solomon, et al.. (2021). Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL. Blood. 138(Supplement 1). 650–650.
14.
Ryan, Daniel, Laura F. Newell, Ellen K. Ritchie, et al.. (2019). Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis. Blood. 134(Supplement_1). 3842–3842.
15.
Abramson, Jeremy S., Maria Lia Palomba, Leo I. Gordon, et al.. (2019). Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas. Blood. 134(Supplement_1). 241–241.
16.
Solh, Melhem, Xu Zhang, Stacey Brown, et al.. (2016). Factors Predicting Graft-versus-Host Disease–Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center. Biology of Blood and Marrow Transplantation. 22(8). 1403–1409.
17.
Bashey, Asad, Xu Zhang, Connie A. Sizemore, et al.. (2013). T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation. Journal of Clinical Oncology. 31(10). 1310–1316.
18.
Solomon, Scott R., Stephanie Jacobson, Melissa Sanacore, et al.. (2013). Myeloablative Conditioning With PBSC Grafts For T-Replete Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide Results In Universal Engraftment, Low Rates Of Gvhd, NRM and Excellent Survival Outcomes: An Analysis Of Two Consecutive Phase II Studies From a Single Center. Blood. 122(21). 3351–3351.
19.
Solomon, Scott R., Connie A. Sizemore, Melissa Sanacore, et al.. (2012). Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of a Prospective Phase II Trial. Biology of Blood and Marrow Transplantation. 18(12). 1859–1866.
20.
Solomon, Scott R., Charles S. Carter, John Schindler, et al.. (2002). Optimized clinical-scale culture conditions for ex vivoselective depletion of host-reactive donor lymphocytes: astrategy for GVHD prophylaxis in allogeneic peripheral bloodstem cell transplantation. Cytotherapy. 4(5).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sally Arai Breakdown of academic impact, for papers by Asad Bashey Breakdown of academic impact, for papers by Francesco Lanza Breakdown of academic impact, for papers by Carol Ann Huff Breakdown of academic impact, for papers by A Schattenberg Breakdown of academic impact, for papers by Francis Ayuk Breakdown of academic impact, for papers by Joseph P. McGuirk Breakdown of academic impact, for papers by RE Champlin Breakdown of academic impact, for papers by Panagiotis Kottaridis Breakdown of academic impact, for papers by Harry Dolstra